Sesamol and naringenin reverse the effect of rotenone-induced PD rat model.
In the previous report (Sonia Angeline et al., 2012), we showed an altered expression of protective proteins in rotenone-induced Parkinson's disease (PD)-like rat model. This model exhibited a marked attenuation in the expression of parkin, C terminus Hsp70 interacting protein (CHIP) and PARK 7 protein (DJ1) while enhanced levels of caspases and ubiquitin were seen. Herein, we confirmed the neuroprotective role of sesamol and naringenin individually on rotenone-induced rodent model of PD. Rotenone administration was given for 11days to generate the PD model (Sonia Angeline et al., 2012). From 11th day onward individual doses of sesamol (15mg/kg) and naringenin (10mg/kg) drugs were given orally to the rotenone PD rat model for 10 consecutive days. The impact of drugs markedly improved the motor skills, body weight, expression of parkin, DJ1, tyrosine hydroxylase and CHIP compared to the group treated with rotenone alone in the striatum and substantia nigra. These results were correlated with the reduction in caspase and ubiquitin levels by immunostaining and immunoblotting. Moreover, improved morphology and survivability of neurons were seen upon sesamol and naringenin treatment in the same rat PD model. Further we confirmed the efficacy of neuroprotective biomolecule administration on muscle from the above PD model and observed the restoration in muscle morphology, elevated level of parkin, DJ1, differential expression of heat shock proteins and reduced cell death. To conclude, for the first time we are demonstrating the comprehensive role of sesamol and naringenin (rotenone-induced PD model) in neuro and myoprotection that would have great clinical significance.
Functional Genomics Laboratory, Center for Medical Engineering, Vellore Institute of Technology, Vellore, TN 632014, India.
M
M
Sonia Angeline
A
A
Sarkar
K
K
Anand
R K
RK
Ambasta
P
P
Kumar
D000818:Animals; D052117:Benzodioxoles / Q000627:therapeutic use*; D004195:Disease Models, Animal; D044950:Flavanones / Q000627:therapeutic use*; D008297:Male; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology; D010636:Phenols / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D012402:Rotenone / Q000633:toxicity*
D052117:Benzodioxoles; D044950:Flavanones; D010636:Phenols; D012402:Rotenone; C025583:sesamol; C005273:naringenin
6 hydroxy dopamine; 6-OHD; C terminus Hsp70 interacting protein; CHIP; DA; FITC; H&E; HRP; HSPs; PD; Parkinson’s disease; TH; UPS; dopamine; fluorescein isothiocyanate; heat shock proteins; hematoxylin and eosin; horse radish peroxidase; naringenin; neuroprotection; rotenone; sesamol; tyrosine hydroxylase; ubiquitin proteasome system